3,843 reports of this reaction
2.1% of all TACROLIMUS OINTMENT 0.1% reports
#8 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #8 most commonly reported adverse reaction for TACROLIMUS OINTMENT 0.1%, manufactured by Encube Ethicals, Inc.. There are 3,843 FDA adverse event reports linking TACROLIMUS OINTMENT 0.1% to CYTOMEGALOVIRUS INFECTION. This represents approximately 2.1% of all 181,625 adverse event reports for this drug.
TACROLIMUS OINTMENT 0.1% has an overall safety score of 92 out of 100. Patients taking TACROLIMUS OINTMENT 0.1% who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for TACROLIMUS OINTMENT 0.1%, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for TACROLIMUS OINTMENT 0.1%:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 3,843 FDA reports for TACROLIMUS OINTMENT 0.1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 2.1% of all adverse event reports for TACROLIMUS OINTMENT 0.1%, making it a notable side effect.
If you experience cytomegalovirus infection while taking TACROLIMUS OINTMENT 0.1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.